Boston Scientific To Acquire Silk Road Medical For $1.16B In Cash, Offering $44 Per Share; 30% Premium Over Last Closing Price; Deal To Enhance Neurovascular Portfolio And Close By Q4 2024 Pending Regulatory Approvals

6/20/24 1:21:31 PM ET

$BSX

$SILK

Medical/Dental Instruments

Health Care

Medical/Dental Instruments

Health Care

Get the next $BSX alert in real time by email

Boston Scientific To Acquire Silk Road Medical For $1.16B In Cash, Offering $44 Per Share; 30% Premium Over Last Closing Price; Deal To Enhance Neurovascular Portfolio And Close By Q4 2024 Pending Regulatory Approvals

Get the next $BSX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BSX
$SILK

Company	Date	Price Target	Rating	Analyst
Boston Scientific Corporation $BSX	10/18/2024		Buy → Hold	Needham
Silk Road Medical Inc. $SILK	7/11/2024		Buy → Sell	Argus
Boston Scientific Corporation $BSX	5/30/2024	$90.00	Buy	Goldman
Silk Road Medical Inc. $SILK	3/7/2024	$24.00	Hold → Buy	Argus
Boston Scientific Corporation $BSX	2/1/2024	$65.00 → $80.00	Neutral → Buy	Mizuho
Silk Road Medical Inc. $SILK	1/19/2024	$9.00 → $20.00	Hold → Buy	Stifel
Silk Road Medical Inc. $SILK	1/3/2024	$20.00	Buy	Lake Street
Silk Road Medical Inc. $SILK	10/24/2023		Underperform → Peer Perform	Wolfe Research

More analyst ratings

$BSX
$SILK
Leadership Updates

Live Leadership Updates

SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors
TEL AVIV, Israel, Nov. 14, 2024 /PRNewswire/ -- SoniVie Ltd., a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment of Raymond W. Cohen to serve as its chairman of the board of directors. Mr. Cohen has served as the chief executive officer and member of the board of directors of Axonics, Inc., an Irvine, Calif. based global medical technology company he cofounded in 2013 and took public October 31, 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the fastest growing companies in the Americas. Cohen is retiring from Axonics following the close of its $3.7 bi
11/14/24 9:30:00 AM ET
$BSX
Medical/Dental Instruments
Health Care
Silk Road Medical Names Chas McKhann Chief Executive Officer
SUNNYVALE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK) ("Silk Road" or the "Company"), a company focused on reducing the risk of stroke and its devastating impact, today announced that Chas McKhann has been appointed Chief Executive Officer (CEO), effective immediately. Mr. McKhann is an accomplished leader with more than 25 years of experience in the medical device industry, including C-suite positions at seven public and private companies. Most recently, Mr. McKhann served as President and CEO of Apollo Endosurgery (acquired by Boston Scientific in April 2023), where he created and led a transformational growth strategy for the company's minimal
11/2/23 8:00:00 AM ET
$SILK
Medical/Dental Instruments
Health Care
Silk Road Medical Announces Retirement of CEO Erica Rogers
Working with Leading Executive Search Firm to Identify Successor SUNNYVALE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that CEO Erica Rogers plans to retire from the Company following the completion of a succession process. The Company is working with Spencer Stuart, a leading executive search firm. To ensure a smooth transition, Ms. Rogers will remain as President and CEO of the Company until her successor is appointed. "I'd like to thank Erica for her tremendous contributions to Silk Road over the last 11 years. Erica has been integral in leading and expand
10/10/23 4:20:00 PM ET
$SILK
Medical/Dental Instruments
Health Care

$BSX
$SILK
Financials

Live finance-specific insights

Boston Scientific Announces Results for Third Quarter 2024
MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.
10/23/24 6:30:00 AM ET
$BSX
$SILK
Medical/Dental Instruments
Health Care
Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results
-Company to also host virtual webcast with a cardiology business update- MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2024, on Wednesday, October 23, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter on October 23 prior to the conference call.
10/2/24 8:00:00 AM ET
$BSX
Medical/Dental Instruments
Health Care
Boston Scientific Announces Results for Second Quarter 2024
MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per share (EPS), compared to $261 million or $0.18 per share a year ago, and achieved adjusted3 EPS of $0.62 for the period, compared to $0.53 a year ago.
7/24/24 6:30:00 AM ET
$BSX
$SILK
Medical/Dental Instruments
Health Care

$BSX
$SILK
Press Releases

Fastest customizable press release news feed in the world

Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO, Nov. 16, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Key findings from the study comparing the device to first-line oral anticoagulation (OAC) – including direct oral anticoagulants (DOAC) (95%) and warfarin (5%) – for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablatio
11/16/24 3:07:00 PM ET
$BSX
Medical/Dental Instruments
Health Care
Boston Scientific Closes Acquisition of Axonics, Inc.
MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (NASDAQ:AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. "Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence," said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. "By closing this acquisiti
11/15/24 8:43:00 AM ET
$AXNX
$BSX
Medical/Dental Instruments
Health Care
SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors
TEL AVIV, Israel, Nov. 14, 2024 /PRNewswire/ -- SoniVie Ltd., a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment of Raymond W. Cohen to serve as its chairman of the board of directors. Mr. Cohen has served as the chief executive officer and member of the board of directors of Axonics, Inc., an Irvine, Calif. based global medical technology company he cofounded in 2013 and took public October 31, 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the fastest growing companies in the Americas. Cohen is retiring from Axonics following the close of its $3.7 bi
11/14/24 9:30:00 AM ET
$BSX
Medical/Dental Instruments
Health Care

Boston Scientific To Acquire Silk Road Medical For $1.16B In Cash, Offering $44 Per Share; 30% Premium Over Last Closing Price; Deal To Enhance Neurovascular Portfolio And Close By Q4 2024 Pending Regulatory Approvals

Chat with this insight

Recent Analyst Ratings for $BSX$SILK

$BSX$SILK Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Silk Road Medical Inc.

SEC Form SC 13D filed by Silk Road Medical Inc.

Amendment: SEC Form SC 13G/A filed by Silk Road Medical Inc.

$BSX$SILK Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$BSX$SILK Market Insights

Live Market Insights

Director Ludwig Edward J sold $446,902 worth of shares (4,877 units at $91.63), decreasing direct ownership by 11% to 39,398 units (SEC Form 4)

EVP, Global Operations Sorenson John Bradley gifted 2,610 shares, decreasing direct ownership by 7% to 37,096 units (SEC Form 4)

EVP, Global Operations Sorenson John Bradley exercised 17,362 shares at a strike of $24.55 and sold $2,680,572 worth of shares (30,580 units at $87.66), decreasing direct ownership by 25% to 39,706 units (SEC Form 4)

Apple To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday

JP Morgan Maintains Overweight on Boston Scientific, Raises Price Target to $85

Canaccord Genuity Maintains Buy on Boston Scientific, Raises Price Target to $88

$BSX$SILK SEC Filings

Boston Scientific Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Boston Scientific Corporation filed SEC Form 8-K: Regulation FD Disclosure

$BSX$SILK Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Ballinger Kevin J. bought $198,783 worth of shares (11,700 units at $16.99), increasing direct ownership by 192% to 17,807 units (SEC Form 4)

$BSX$SILK Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Boston Scientific downgraded by Needham

Silk Road Medical downgraded by Argus

Goldman initiated coverage on Boston Scientific with a new price target

$BSX$SILK Leadership Updates

Live Leadership Updates

SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors

Silk Road Medical Names Chas McKhann Chief Executive Officer

Silk Road Medical Announces Retirement of CEO Erica Rogers

$BSX$SILK Financials

Live finance-specific insights

Boston Scientific Announces Results for Third Quarter 2024

Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results

Boston Scientific Announces Results for Second Quarter 2024

$BSX$SILK Press Releases

Fastest customizable press release news feed in the world

Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial

Boston Scientific Closes Acquisition of Axonics, Inc.

SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors

$BSX$SILK FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

March 1, 2024 - FDA Roundup: March 1, 2024

Recent Analyst Ratings for
$BSX
$SILK

$BSX
$SILK
Large Ownership Changes

$BSX
$SILK
Insider Trading

$BSX
$SILK
Market Insights

$BSX
$SILK
SEC Filings

$BSX
$SILK
Insider Purchases

$BSX
$SILK
Analyst Ratings

$BSX
$SILK
Leadership Updates

$BSX
$SILK
Financials

$BSX
$SILK
Press Releases

$BSX
$SILK
FDA approvals